ALXN - Alexion Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
124.52
+2.61 (+2.14%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close121.91
Open122.39
Bid122.39 x 800
Ask124.95 x 900
Day's Range121.86 - 124.77
52 Week Range102.10 - 149.34
Volume1,032,879
Avg. Volume1,739,439
Market Cap27.706B
Beta1.05
PE Ratio (TTM)53.56
EPS (TTM)2.33
Earnings DateJul 25, 2018 - Jul 30, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est158.79
Trade prices are not sourced from all markets
  • Alexion (ALXN) Submits Application for ALXN1210 with FDA
    Zacks15 hours ago

    Alexion (ALXN) Submits Application for ALXN1210 with FDA

    Alexion Pharmaceuticals, Inc. (ALXN) submits a Biologics License Application (BLA) to the FDA for approval of ALXN1210 to treat patients with paroxysmal nocturnal hemoglobinuria (PNH).

  • Biotech Stock Roundup: SRPT & SLDB Soar on Positive Data, ANIK & ZIOP Crash
    Zacksyesterday

    Biotech Stock Roundup: SRPT & SLDB Soar on Positive Data, ANIK & ZIOP Crash

    The biotech sector showed volatility with a few companies gaining on positive data readouts while a few plunging on dismal results.

  • TheStreet.comyesterday

    5 Stocks That Are Screaming Buys Right Now

    Here we used TipRanks' stock screener to pinpoint the most compelling stocks right now. The Street is buzzing about Neurocrine's Ingrezza drug, the first FDA-approved treatment for adults with tardive dyskinesia. On its first quarter earnings call, Neurocrine updated the Street with respect to ongoing market penetration for Ingrezza.

  • Future home of PTC, Alexion could sell for $450M
    American City Business Journalsyesterday

    Future home of PTC, Alexion could sell for $450M

    The 17-story office at 121 Seaport Blvd. will be the future headquarters of industrial software company PTC, which is relocating from Needham, and Alexion Pharmaceuticals, which is relocating from New Haven, Connecticut.

  • Why This Biotech Company Could Shock 2019 Sales Expectations
    Investor's Business Daily2 days ago

    Why This Biotech Company Could Shock 2019 Sales Expectations

    Alexion surprised Wall Street on Tuesday when it asked the FDA for an expedited review of its newest rare-disease drug, ALXN1210.

  • Business Wire2 days ago

    Alexion Submits Application for Priority Review and Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the U.S.

    Alexion Pharmaceuticals, Inc. (ALXN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval of ALXN1210, the Company’s investigational long-acting C5 complement inhibitor, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). “This first regulatory submission is an important step toward our goal of establishing ALXN1210 as the new standard of care for patients with PNH, building on 10 years of proven efficacy and safety with Soliris®, and 25 years of leadership in complement biology,” said John Orloff, M.D., Executive Vice President and Head of Research & Development at Alexion.

  • Barrons.com6 days ago

    Big Biotech Set for Earnings Blowout?

    Earlier this year, Oppenheimer's Hartaj Singh argued that earnings expectations were too high for big biotech companies heading into the first-quarter reporting season. Ahead of the reports, due out in mid-July, Singh argues that fundamentals for large-cap biotech, as well as sector sentiment are "slowly but surely improving," leading him to believe that the stocks could outperform, led by Gilead Sciences (GILD), Alexion Pharmaceuticals (ALXN), and Vertex Pharmaceuticals (VRTX). For Gilead, he's upbeat about a more stable pricing environment for hepatitis C treatments, while investors are getting more interested in the company's "budding" immunology and nonalcoholic steatohepatitis (NASH) franchises, setting up an attractive risk-reward profile going into the second quarter.  Alexion reported "stellar" first-quarter earnings, and Singh sees another strong quarter ahead, and he wonders "when the Street will start giving management credit for relentless execution." Vertex is one of his favorite large-cap biotechs, and he sees a good report ahead, along with an update about the progress of its cystic-fibrosis drugs.

  • Business Wire7 days ago

    Alexion Announces Selection of Positive Phase 3 Clinical Data for ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) for Late-Breaking Oral Presentation at Annual Conference of the European Hematology Association (EHA)

    Alexion Pharmaceuticals, Inc. (ALXN) today announced that positive results from one of the two large Phase 3 studies of ALXN1210, the Company’s investigational long-acting C5 complement inhibitor, in patients with paroxysmal nocturnal hemoglobinuria (PNH) were selected for presentation during the Late-Breaking Oral Session (at 11:45 a.m. CET) on Sunday, June 17, 2018 at the Annual Conference of the European Hematology Association (EHA) in Stockholm, Sweden. “We are very excited about EHA’s recognition of the robustness and importance of these data in complement inhibitor treatment-naïve patients.

  • Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod
    Zacks8 days ago

    Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod

    Key areas of focus in the biotech space include regulatory approvals and licensing/acquisition deals.

  • ACCESSWIRE8 days ago

    Wired News – Alexion Pharma and Complement Pharma Inked Deal to Co-develop Preclinical C6 Complement Inhibitor CP010

    LONDON, UK / ACCESSWIRE / June 13, 2018 / If you want access to our free research report on Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) ("Alexion"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ALXN as the Company's latest news hit the wire. On June 11, 2018, the Company announced that it has signed a partnership deal with Complement Pharma to co-develop the preclinical C6 complement inhibitor CP010 for neurodegenerative disorders. Active-Investors.com is currently working on the research report for Unity Biotechnology, Inc. (NASDAQ: UBX), which also belongs to the Healthcare sector as the Company Alexion Pharma.

  • Alexion-Complement Pharma Tie Up to Treat Neuro Disorders
    Zacks9 days ago

    Alexion-Complement Pharma Tie Up to Treat Neuro Disorders

    Alexion (ALXN) teams up with Complement Pharma to co-develop its C6 inhibitor, CP010, for neurodegenerative disorders.

  • Business Wire10 days ago

    Alexion and Complement Pharma Announce Partnership to Co-Develop Pre-Clinical Complement Inhibitor for Neurodegenerative Disorders

    Alexion Pharmaceuticals, Inc. (ALXN) and Complement Pharma today announced a partnership to co-develop the preclinical C6 complement inhibitor CP010 for neurodegenerative disorders. C6 inhibition prevents the formation of the destructive membrane attack complex (MAC), a complex of terminal complement proteins that mediate cellular injury following complement activation, and has the potential to treat a variety of central nervous system disorders. Under the terms of the agreement, Alexion will provide Complement Pharma with up to € 14 million in milestone-dependent payments through Phase 1b development.

  • ACCESSWIRE10 days ago

    Stock Performance Review on Alder Biopharma and Three Other Biotech Stocks

    LONDON, UK / ACCESSWIRE / June 11, 2018 / If you want a free Stock Review on ALDR sign up now at www.wallstequities.com/registration. Gains were broad based as seven out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Alder Biopharmaceuticals Inc. (NASDAQ: ALDR), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), and Altimmune Inc. (NASDAQ: ALT).

  • See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
    Markit13 days ago

    See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.

    Alexion Pharmaceuticals Inc NASDAQ/NGS:ALXN

  • Why Alexion's Blockbuster Franchise Is Safe From Copycats — For Now
    Investor's Business Daily16 days ago

    Why Alexion's Blockbuster Franchise Is Safe From Copycats — For Now

    Alexion Pharmaceuticals will likely keep 75% of its Soliris market in the U.S. even as rivals like Amgen try to copy the blockbuster drug, an analyst said Tuesday in a bullish note.

  • Business Wire16 days ago

    Alexion to Present at the Goldman Sachs 39th Annual Global Healthcare Conference

    Alexion Pharmaceuticals today announced that management will present at the Goldman Sachs 39th Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Tuesday, June 12, 2018 at 11:20 a.m., PDT.

  • Biotech Stock Roundup: GILD Epclusa's China Approval, BMRN Palynziq's FDA Nod
    Zacks22 days ago

    Biotech Stock Roundup: GILD Epclusa's China Approval, BMRN Palynziq's FDA Nod

    The biotech sector grabbed headlines last week with drug approvals and licensing deals. Investors will await pipeline development news at the ASCO in the coming week.

  • ACCESSWIRE22 days ago

    Wired News – Alexion Pharma Announced Acceptance of Offer by Wilson Therapeutics

    LONDON, UK / ACCESSWIRE / May 30, 2018 / If you want access to our free research report on Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) ("Alexion"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ALXN as the Company's latest news hit the wire. On May 25, 2018, the Company announced that its offer, through a wholly owned subsidiary, for the shares in Sweden-based Wilson Therapeutics has been accepted by shareholders, representing 97.7% of the total number of shares and votes in Wilson Therapeutics. Active-Investors.com is currently working on the research report for CEL-SCI Corporation (NYSE AMER: CVM), which also belongs to the Healthcare sector as the Company Alexion Pharma.

  • A Look at Incyte’s Valuation as of May 25
    Market Realist23 days ago

    A Look at Incyte’s Valuation as of May 25

    Incyte Corporation (INCY) is a biopharmaceutical company with headquarters in Wilmington, Delaware. Incyte’s business includes the discovery, development, and commercialization of various products to cater to unmet medical needs in oncology and the treatment of other diseases.

  • Why is Alexion (ALXN) Down 3.5% Since its Last Earnings Report?
    Zacks24 days ago

    Why is Alexion (ALXN) Down 3.5% Since its Last Earnings Report?

    Alexion (ALXN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Benzinga27 days ago

    Benzinga's Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck's Cancer Drug Review Extended

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks Here are the biotech stocks that were hitting 52-week highs May 24:  ArQule, Inc. (NASDAQ: ARQL ) Baxter ...

  • Business Wire27 days ago

    Alexion Offer for Wilson Therapeutics Accepted

    Alexion Pharmaceuticals, Inc. (ALXN) today announced that its offer, through a wholly owned subsidiary, for the shares in Wilson Therapeutics has been accepted by shareholders representing 97.7 percent of the total number of shares and votes in Wilson Therapeutics. “The acquisition of Wilson Therapeutics is a key first step in rebuilding our pipeline,” said Ludwig Hantson, Ph.D., Chief Executive Officer of Alexion. In order to give Wilson Therapeutics’ shareholders additional time to accept the offer, Alexion has extended the acceptance period until June 8, 2018.

  • Vivus Stock Rose 60% Last Week
    Market Realistlast month

    Vivus Stock Rose 60% Last Week

    Vivus (VVUS) rose 60% between May 11 and May 18. Headquartered in Cambell, California, Vivus is a fast-growing healthcare company focused on the development of innovative therapies for obesity, sexual health, and sleep. In May 2018, Vivus entered an agreement with Johnson & Johnson (JNJ) to acquire all product rights of Janssen Pharmaceuticals’ Pancreaze in the United States.

  • Analyzing Alexion’s Cash Flows and Valuation Metrics
    Market Realistlast month

    Analyzing Alexion’s Cash Flows and Valuation Metrics

    Since the start of 2018, Alexion Pharmaceuticals (ALXN) has fallen -2.5% to close at $121 as of May 16. Alexion Pharmaceuticals generated $300 million from operating activities in the first quarter of 2018 compared to $308 million in the first quarter of 2017. In the first quarter of 2018, Alexion Pharmaceuticals used $254.7 million in investing activities compared to $495.3 million in the first quarter of 2017.

  • Market Realistlast month

    Exploring the Promising Research Pipeline of Alexion Therapeutics

    Alexion Pharmaceuticals (ALXN) is conducting two Phase 3 clinical studies in patients suffering from aHUS (atypical hemolytic uremic syndrome), which leads to life-threatening damage to the kidney, brain, heart, and other critical organs. This plan entails a once-per-week dosing to PNH (paroxysmal nocturnal hemoglobinuria) patients to support registration in PNH as well as aHUS.